Vertex Pharmaceuticals’ (Nasdaq: VRTX) Trikafta (elexacaftor/tezacaftor/ivacaftor) comes with evidence of providing a major net benefit for patients, but the price tag needs to be massively reduced to align with these benefits.
That is the conclusion of the Institute for Clinical and Economic Review (ICER) in its evidence report on the new treatment for cystic fibrosis (CF), which was released this week and recommended a health-benefit price benchmark of Trikafta for $67,900 to $85,500 per year, which would require at least a 73% discount off the current list price.
'Prices are out of proportion to substantial benefits'
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze